BR112014018284A2 - antagonistas do peptídeo relacionado ao gene modificado da calcitonina, composição farmacêutica, métodos para tratar cefaleia e condição associada a níveis anormais do cgrp e usos de antagonista do peptídeo relacionado ao gene modificado da calcitonina e de composição farmacêutica - Google Patents

antagonistas do peptídeo relacionado ao gene modificado da calcitonina, composição farmacêutica, métodos para tratar cefaleia e condição associada a níveis anormais do cgrp e usos de antagonista do peptídeo relacionado ao gene modificado da calcitonina e de composição farmacêutica

Info

Publication number
BR112014018284A2
BR112014018284A2 BR112014018284A BR112014018284A BR112014018284A2 BR 112014018284 A2 BR112014018284 A2 BR 112014018284A2 BR 112014018284 A BR112014018284 A BR 112014018284A BR 112014018284 A BR112014018284 A BR 112014018284A BR 112014018284 A2 BR112014018284 A2 BR 112014018284A2
Authority
BR
Brazil
Prior art keywords
calcitonin
pharmaceutical composition
related peptide
modified gene
methods
Prior art date
Application number
BR112014018284A
Other languages
English (en)
Other versions
BR112014018284B1 (pt
Inventor
J Soares Christopher
Original Assignee
J Soares Christopher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J Soares Christopher filed Critical J Soares Christopher
Publication of BR112014018284A2 publication Critical patent/BR112014018284A2/pt
Publication of BR112014018284B1 publication Critical patent/BR112014018284B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57527—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112014018284-1A 2012-01-26 2013-01-25 Antagonista de peptídeo relacionado ao gene da calcitonina, composições farmacêuticas e uso dos mesmos BR112014018284B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261591236P 2012-01-26 2012-01-26
US61/591,236 2012-01-26
PCT/US2013/023260 WO2013112912A1 (en) 2012-01-26 2013-01-25 Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use

Publications (2)

Publication Number Publication Date
BR112014018284A2 true BR112014018284A2 (pt) 2017-07-04
BR112014018284B1 BR112014018284B1 (pt) 2023-08-01

Family

ID=

Also Published As

Publication number Publication date
IL233655A0 (en) 2014-08-31
MX2014008960A (es) 2015-01-16
AU2013211929B2 (en) 2016-05-26
CN104271596A (zh) 2015-01-07
US9193776B2 (en) 2015-11-24
JP2015513318A (ja) 2015-05-07
RU2014131605A (ru) 2016-03-20
EP3272769B1 (en) 2020-06-17
NO2864579T3 (pt) 2018-01-20
EP2807187B1 (en) 2017-07-26
US20160145315A1 (en) 2016-05-26
AU2013211929A1 (en) 2014-09-11
KR101855242B1 (ko) 2018-05-09
JP6411425B2 (ja) 2018-10-24
EP3272769A1 (en) 2018-01-24
RU2017119773A (ru) 2018-12-06
KR20140132342A (ko) 2014-11-17
US20140329752A1 (en) 2014-11-06
DK2807187T3 (en) 2017-09-11
ES2819825T3 (es) 2021-04-19
RU2742826C2 (ru) 2021-02-11
IL252555A0 (en) 2017-07-31
RU2624016C2 (ru) 2017-06-30
HK1201068A1 (en) 2015-08-21
KR20170071613A (ko) 2017-06-23
EP2807187A1 (en) 2014-12-03
RU2017119773A3 (pt) 2020-11-18
ES2641325T3 (es) 2017-11-08
MX347229B (es) 2017-04-19
CA2861392C (en) 2021-08-17
HK1249915A1 (zh) 2018-11-16
AU2016205801A1 (en) 2016-08-04
US20170204155A1 (en) 2017-07-20
US10370425B2 (en) 2019-08-06
IL252555B (en) 2020-06-30
JP6025871B2 (ja) 2016-11-16
CA2861392A1 (en) 2013-08-01
IL233655A (en) 2017-06-29
CN108997490A (zh) 2018-12-14
WO2013112912A1 (en) 2013-08-01
JP2017036308A (ja) 2017-02-16
KR102052983B1 (ko) 2019-12-06
JP2019006821A (ja) 2019-01-17
CN104271596B (zh) 2018-09-18

Similar Documents

Publication Publication Date Title
BR112015002085A2 (pt) proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção
HK1215378A1 (zh) 藥物組合物、治療方法及其用途
BR112014021103A8 (pt) anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
BR112015013410A2 (pt) método para biosintetizar um ou mais produtos e hospedeiro recombinante
BR112014023937A2 (pt) composição farmacêutica, agente farmacêutico de combinação e método de tratamento
BR112015000437A2 (pt) imunoconjugados, formulação farmacêutica, métodos de tratamento e de inbir a proliferação de uma célula
BR112015007061A2 (pt) composto, composição farmacêutica e método para tratar uma condição ou distúrbio dependente de apkc em um paciente
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
HK1206264A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof -3-
SI2729151T1 (sl) Farmacevtski sestavek, postopki za zdravljenje in njihove uporabe
BR112014032510A2 (pt) composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto.
BR112014010290A2 (pt) composição farmacêutica, métodos, composições e usos
EP2889308A4 (en) SUPERFAMIL ALPHA O CONOTOXIN PEPTIDE, PHARMACEUTICAL COMPOSITION AND USE THEREOF
BR112014031896A2 (pt) composto, composição farmacêutica, e, método para o tratamento de um distúrbio
AP2015008599A0 (en) Pharmaceutical composition for treating headache, and preparation method thereof
BR112015003927A2 (pt) filete ou listra de segurança, processo para fazer o filete ou listra de segurança, uso do filete ou listra de segurança, documento de segurança e processo para fazer o substrato de segurança.
EP2842568A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF TYPE I DIABETES AND THE USE THEREOF
BR112014016744A2 (pt) polipeptídeo, composição farmacêutica e método para a produção de um ou mais polipeptídeos
BR112014015753A8 (pt) derivado do polímero da quitosana, composição farmacêutica, método para o tratamento, utilização e presente invenção
BR112014025339A8 (pt) método para tratamento ou prevenção ou redução de infecção do virus influenza e composição farmacêutica para o mesmo.
ZA201409508B (en) Pharmaceutical composition comprising fimasartan and hydrochlorothiazide
BR112014016736A8 (pt) composto, composição farmacêutica, método para tratamento, uso de um composto e invenção
BR112015010797A2 (pt) compostos aniônicos substituídos, e, composição farmacêutica
BR112015010271A2 (pt) produto de comicronização, composição farmacêutica e seus usos
BR112013017267A2 (pt) formulação de lipossomas, suspensão e composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/01/2013, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.